KEN
Kenon Holdings Ltd.
Independent Power Producers
Market Cap$4.52B
5Y Perf.+322.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KEN vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$41.93B
5Y Perf.+187.4%
KEN vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KEN | TEVA |
|---|---|---|
| Industry | Independent Power Producers | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.52B | $41.93B |
| Revenue (TTM) | $775M | $17.35B |
| Net Income (TTM) | $495M | $1.56B |
| Gross Margin | 17.1% | 52.1% |
| Operating Margin | 5.0% | 13.2% |
| Forward P/E | 7.6x | 14.5x |
| Total Debt | $1.28B | $17.38B |
| Cash & Equiv. | $1.02B | $3.56B |
KEN vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KEN
TEVA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Kenon Holdings Ltd. (KEN) | 100 | 422.8 | +322.8% |
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KEN vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KEN leads in 7 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
KEN
Kenon Holdings Ltd.
The Income Pick
KEN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.90, yield 4.4%
- Rev growth 8.6%, EPS growth 356.6%, 3Y rev CAGR 15.5%
- 12.6% 10Y total return vs TEVA's -28.3%
Best for: income & stability and growth exposure
TEVA
Teva Pharmaceutical Industries Limited
The Value Angle
In this particular matchup, TEVA is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KEN | 8.6% revenue growth vs TEVA's 4.3% |
| Value | KEN | Lower P/E (7.6x vs 14.5x) |
| Quality / Margins | KEN | 63.8% margin vs TEVA's 9.0% |
| Stability / Safety | KEN | Beta 0.90 vs TEVA's 1.13, lower leverage |
| Dividends | KEN | 4.4% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | KEN | +194.0% vs TEVA's +104.6% |
| Efficiency (ROA) | KEN | 11.4% ROA vs TEVA's 3.9%, ROIC 1.2% vs 7.7% |
KEN vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
KEN vs TEVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKENLAGGINGTEVA
TEVATeva Pharmaceutical I…
0leads
KENKenon Holdings Ltd.
0leads
6 Total Categories
CATEGORYLEADERvs TEVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — KEN and TEVA each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 22.4x KEN's $775M. KEN is the more profitable business, keeping 63.8% of every revenue dollar as net income compared to TEVA's 9.0%. On growth, KEN holds the edge at +8.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KENKenon Holdings Lt… | TEVATeva Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $775M | $17.3B |
| EBITDAEarnings before interest/tax | $122M | $3.3B |
| Net IncomeAfter-tax profit | $495M | $1.6B |
| Free Cash FlowCash after capex | $222M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +17.1% | +52.1% |
| Operating MarginEBIT ÷ Revenue | +5.0% | +13.2% |
| Net MarginNet income ÷ Revenue | +63.8% | +9.0% |
| FCF MarginFCF ÷ Revenue | +28.6% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.3% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -95.3% | +72.2% |
Evenly matched — KEN and TEVA each lead in 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — KEN and TEVA each lead in 2 of 4 comparable metrics.
Valuation Metrics
At 7.6x trailing earnings, KEN trades at a 75% valuation discount to TEVA's 30.0x P/E. On an enterprise value basis, TEVA's 17.6x EV/EBITDA is more attractive than KEN's 33.9x.
| Metric | KENKenon Holdings Lt… | TEVATeva Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $4.5B | $41.9B |
| Enterprise ValueMkt cap + debt − cash | $4.8B | $55.8B |
| Trailing P/EPrice ÷ TTM EPS | 7.64x | 30.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.55x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 33.93x | 17.65x |
| Price / SalesMarket cap ÷ Revenue | 6.01x | 2.43x |
| Price / BookPrice ÷ Book value/share | 1.72x | 5.34x |
| Price / FCFMarket cap ÷ FCF | — | 36.52x |
Evenly matched — KEN and TEVA each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
Evenly matched — KEN and TEVA each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $19 for KEN. KEN carries lower financial leverage with a 0.48x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x.
| Metric | KENKenon Holdings Lt… | TEVATeva Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | +19.1% | +20.7% |
| ROA (TTM)Return on assets | +11.4% | +3.9% |
| ROICReturn on invested capital | +1.2% | +7.7% |
| ROCEReturn on capital employed | +1.2% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 8 |
| Debt / EquityFinancial leverage | 0.48x | 2.20x |
| Net DebtTotal debt minus cash | $264M | $13.8B |
| Cash & Equiv.Liquid assets | $1.0B | $3.6B |
| Total DebtShort + long-term debt | $1.3B | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | 0.52x | 2.51x |
Evenly matched — KEN and TEVA each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — KEN and TEVA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $34,065 for KEN. Over the past 12 months, KEN leads with a +194.0% total return vs TEVA's +104.6%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs KEN's 51.4% — a key indicator of consistent wealth creation.
| Metric | KENKenon Holdings Lt… | TEVATeva Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | +34.0% | +16.3% |
| 1-Year ReturnPast 12 months | +194.0% | +104.6% |
| 3-Year ReturnCumulative with dividends | +246.9% | +297.5% |
| 5-Year ReturnCumulative with dividends | +240.6% | +246.2% |
| 10-Year ReturnCumulative with dividends | +1256.7% | -28.3% |
| CAGR (3Y)Annualised 3-year return | +51.4% | +58.4% |
Evenly matched — KEN and TEVA each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KEN and TEVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
KEN is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than TEVA's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs KEN's 90.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KENKenon Holdings Lt… | TEVATeva Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 1.13x |
| 52-Week HighHighest price in past year | $95.93 | $37.35 |
| 52-Week LowLowest price in past year | $30.42 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +90.3% | +96.4% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 73.5 |
| Avg Volume (50D)Average daily shares traded | 26K | 6.6M |
Evenly matched — KEN and TEVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KEN as "Hold" and TEVA as "Buy". KEN is the only dividend payer here at 4.39% yield — a key consideration for income-focused portfolios.
| Metric | KENKenon Holdings Lt… | TEVATeva Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | — | $39.00 |
| # AnalystsCovering analysts | 1 | 46 |
| Dividend YieldAnnual dividend ÷ price | +4.4% | — |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | $3.80 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
Both stocks are evenly matched across all financial categories.
Best OverallKenon Holdings Ltd. (KEN)Leads 0 of 6 categories
Loading custom metrics...
KEN vs TEVA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KEN or TEVA a better buy right now?
For growth investors, Kenon Holdings Ltd.
(KEN) is the stronger pick with 8. 6% revenue growth year-over-year, versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). Kenon Holdings Ltd. (KEN) offers the better valuation at 7. 6x trailing P/E, making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KEN or TEVA?
On trailing P/E, Kenon Holdings Ltd.
(KEN) is the cheapest at 7. 6x versus Teva Pharmaceutical Industries Limited at 30. 0x.
03Which is the better long-term investment — KEN or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to +240. 6% for Kenon Holdings Ltd. (KEN). Over 10 years, the gap is even starker: KEN returned +1257% versus TEVA's -28. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KEN or TEVA?
By beta (market sensitivity over 5 years), Kenon Holdings Ltd.
(KEN) is the lower-risk stock at 0. 90β versus Teva Pharmaceutical Industries Limited's 1. 13β — meaning TEVA is approximately 26% more volatile than KEN relative to the S&P 500. On balance sheet safety, Kenon Holdings Ltd. (KEN) carries a lower debt/equity ratio of 48% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — KEN or TEVA?
By revenue growth (latest reported year), Kenon Holdings Ltd.
(KEN) is pulling ahead at 8. 6% versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). On earnings-per-share growth, the picture is similar: Kenon Holdings Ltd. grew EPS 356. 6% year-over-year, compared to 182. 8% for Teva Pharmaceutical Industries Limited. Over a 3-year CAGR, KEN leads at 15. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KEN or TEVA?
Kenon Holdings Ltd.
(KEN) is the more profitable company, earning 79. 6% net margin versus 8. 2% for Teva Pharmaceutical Industries Limited — meaning it keeps 79. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus 6. 3% for KEN. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — KEN or TEVA?
In this comparison, KEN (4.
4% yield) pays a dividend. TEVA does not pay a meaningful dividend and should not be held primarily for income.
08Is KEN or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Kenon Holdings Ltd.
(KEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 4. 4% yield, +1257% 10Y return). Both have compounded well over 10 years (KEN: +1257%, TEVA: -28. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KEN and TEVA?
These companies operate in different sectors (KEN (Utilities) and TEVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: KEN is a small-cap deep-value stock; TEVA is a mid-cap quality compounder stock. KEN pays a dividend while TEVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(KEN: 8.3% · TEVA: 2.3%)Net Margin>
%
(KEN: 63.8% · TEVA: 9.0%)P/E Ratio<
x
(KEN: 7.6x · TEVA: 30.0x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.